Tampa biotech firm elevates board member to president, CEO

Oragenics Inc. (NYSE: OGEN), a Tampa-based biotech company that focuses on treatments for infectious diseases, including COVID-19, has named Kimberly Murphy president and CEO.

Murphy, according to a news release, has served on Oragenics’ board of directors since 2020. She brings more than 25 years of industry experience to her new roles, having most recently served as vice president of GSK, where she was part of the teams charged with developing vaccines for influenza and shingles.